Q32 BioFRA:DB0 -0.18%17 Net Debt Paydown Yield % is 1.41% as of Jul. 07, 2026, which is 72% below its 10-year median of 4.95. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,159 Biotechnology companies, Q32 Bio ranks better than 77.05% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Q32 Bio's Net Debt Paydown Yield % was 1.41%.
Q32 Bio (FRA:DB0) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
The historical data trend for Q32 Bio's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DB0 vs CAMP, CDXS, KROS: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Q32 Bio's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Q32 Bio's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 1.41% mean?
Q32 Bio (FRA:DB0) has a Net Debt Paydown Yield % of 1.41% as of Jul. 07, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Q32 Bio and its competitors. This is 72% below median its historical median of 4.95. Over the past decade, Q32 Bio's Net Debt Paydown Yield % has ranged from 1.41 to 104.31. According to the industry distribution chart, Q32 Bio ranks #266 out of 1159 companies in the Biotechnology industry, placing it in the top 23%.
Is Q32 Bio's Net Debt Paydown Yield % too high?
Q32 Bio's current Net Debt Paydown Yield % of 1.41% is 72% below median its 10-year median of 4.95. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 104.31. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Q32 Bio's value of 1.41% is 4600% above this industry median. Based on the distribution chart, Q32 Bio ranks #266 out of 1159 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Net Debt Paydown Yield % compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #266 out of 1159 companies for Net Debt Paydown Yield %. This places Q32 Bio in the top 23% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. Q32 Bio's value of 1.41% is 4600% above this benchmark. Historically, Q32 Bio's own Net Debt Paydown Yield % has ranged from 1.41 to 104.31 over the past decade. While the company's 10-year median is 4.95 vs. the industry median of 0.03, Q32 Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q32 Bio's current Net Debt Paydown Yield % of 1.41% is 4600% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Q32 Bio and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q32 Bio's current Net Debt Paydown Yield % is 1.41%, which is 72% below median its own 10-year median of 4.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current Net Debt Paydown Yield % of 1.41%. The current Net Debt Paydown Yield % is 1.41%, which is 72% below median its 10-year median of 4.95 and 4600% above the Biotechnology industry median of 0.03. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current Net Debt Paydown Yield % is 1.41% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score
Get the complete analysis for FRA:DB0
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DB0 has been successfully added to your 
